SCHEMBL4855150

SCHEMBL4855150

COC(=O)CCc1ccc(Nc2cc(Cl)ccc2C(=O)OC)c(N)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.50
MAPT P10636 5/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 1/20 0.41
SIRT2 Q8IXJ6 1/20 0.41
CCR9 P51686 2/20 0.41
GAA P10253 4/20 0.40
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 2/20 0.40
HSD17B10 Q99714 2/20 0.40
HPGD P15428 2/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
KCNH2 Q12809 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
TP53 P04637 1/20 0.38
GFER P55789 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4852723 0.89 ABL1 (0.52) ABL1MAPTMEN1KMT2ALMNA
SCHEMBL4855385 0.87 ABL1 (0.56) ABL1MAPTMEN1KMT2ALMNA
SCHEMBL4856252 0.83 PKM (0.44) MAPTKMT2ALMNACCR9HPGD
SCHEMBL4854740 0.81 ABL1 (0.60) ABL1MAPTMEN1KMT2AGAA
SCHEMBL4857888 0.80 CHKA (0.46) ABL1MAPTMEN1KMT2ALMNA
SCHEMBL1290704 0.80 KDM4E (0.60) ABL1MAPTMEN1KMT2ALMNA
SCHEMBL4858225 0.80 ABL1 (0.52) ABL1MAPTMEN1KMT2ALMNA
SCHEMBL4855887 0.79 ABL1 (0.57) ABL1MAPTMEN1KMT2ALMNA
SCHEMBL4856783 0.77 HCRTR1 (0.53) ABL1MAPTMEN1KMT2ALMNA
SCHEMBL4853821 0.77 ABL1 (0.61) ABL1MAPTMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1606268-B1 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS ABBVIE INC (US) 2015-05-20 EP disclosed
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed
EP-1606268-A1 HETEROCYCLIC KINASE INHIBITORS Abbott Laboratories (US) 2005-12-21 EP disclosed
US-20040254159-A1 Heterocyclic kinase inhibitors ABBOTT LABORATORIES 2004-12-16 US disclosed
WO-2004076424-A1 HETEROCYCLIC KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254159-A1 Heterocyclic kinase inhibitors MAP3K20, MAP3K19, MAP3K1 ABL1 45/4885MAPT 4057/4885MEN1 1677/4885
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 ABL1 32/4885MAPT 3753/4885MEN1 2238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.